

## CHARACTERISTICS OF THE HALOGENATION OF 2-SUBSTITUTED 6-BENZHYDRYL-4(3H)-PYRIMIDINONES

I. A. Novakov, B. S. Orlinson, and M. B. Nawrozkij


The halogenation of 2-substituted 6-benzhydryl-4(3H)-pyrimidinones has been investigated. Bromination with  $\text{Py}\cdot\text{Br}_2$  and iodination with  $\text{I}_2$  solution in alkali occurs exclusively at the CH hydrogen of the benzhydryl group.

**Keywords:** 6-benzhydryl-4(3H)-pyrimidinones, bromination, halogenation, iodination.

Derivatives of 6-benzhydryl-4(3H)-pyrimidinones with alkoxy [1], alkylamino [2], or alkylsulphanyl [3] groups in position 2 of the pyrimidine heterocycle are of considerable interest as antiviral materials. At the same time their analogs containing benzhydryl units in position 6 of the pyrimidine ring, are devoid of anti-HIV1 activity, but possess cytotoxic properties [4].

In a continuation of the study of new derivatives of 6-benzhydryl-4(3H)-pyrimidinones as possible cytotoxic agents, we have investigated the halogenation of 2-amino-6-benzhydryl-4(3H)-pyrimidinone (**1a**) and 6-benzhydryl-2-(methylsulfanyl)-4(3H)-pyrimidinone (**1b**). As a result it has been shown that both bromination and iodination of compound **1a** occurs at the CH group of the benzhydryl fragment, even in the absence of a free radicals initiator, to give 2-amino-6-[bromo(diphenyl)methyl]-4(3H)-pyrimidinone (**2a**) and 2-amino-6-[iodo(diphenyl)methyl]-4(3H)-pyrimidinone (**3**) respectively.

Scheme 1



**1, 2 a R = NH<sub>2</sub>; b R = SME**

---


Volgograd State Technical University, Volgograd 400131, Russia; e-mail: thiouracil@rambler.ru.  
Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 9, 1418-1420, September, 2006. Original article submitted May 19, 2005.

In further study we have shown that bromination of compound **1b** also occurs at the CH group of the benzhydryl fragment to give 6-[bromo(diphenyl)methyl]-2-(methylsulfanyl)-4(3H)-pyrimidinone (**2b**).

The signal of the CH proton of the benzhydryl group (in the region of 5.3 ppm) is absent from the  $^1\text{H}$  NMR spectrum of compounds **2a,b** and **3** but the signal of the C(5)H proton of the pyrimidine ring (in the 5.9-6.0 ppm region) is retained.

It should be noted that the direction of the halogenation is not trivial. It has been shown previously [5] that both bromination and iodination of 6-alkyl- and 6-(aryl methyl)-4(3H)-pyrimidinones occurs exclusively at position 5 of the heterocycle. Since addition, not substitution, is characteristic of pyridine dibromide [6], it is possible that the change in direction of bromination of compounds **1a,b** is connected with the participation of the tautomeric form **A** (Scheme 2), stabilized by two phenyl groups.

Scheme 2



In the case of the iodination reaction, the halogenating reagent is the  $\text{I}^- - \text{IO}^-$  system (the product of the reaction of  $\text{I}_2$  with aqueous alkali) which also indicates that the reaction may proceed by an addition-elimination mechanism.

Compounds **1a,b** were synthesized according to a method described previously [7], by the reaction of methyl (4,4-diphenyl-3-oxo)butanoate (**4**) with guanidine or 5-methylisothiourea respectively.

## EXPERIMENTAL

$^1\text{H}$  NMR spectra of  $\text{DMSO-d}_6$  solution with HMDS as internal standard ( $\delta = 0.05$  ppm) were recorded on a Varian-Mercury 300B (301 MHz). Melting points were determined with MelTemp 3.0 instrument at rate of heating of  $10^\circ\text{C}/\text{min}$ .

**Methyl 4,4-Diphenyl-3-oxobutanoate (4)** was prepared by a method we have described [8]. Yield 98%; bp  $172-174^\circ$  (1-2 mm Hg),  $n^{20}_{\text{D}}$  1.5654 which agree with the literature results [9].

**6-Diphenylmethyl-2-(methylsulfanyl)-4(3H)-pyrimidinone (1b).** A mixture of 50% aqueous solution of  $\text{K}_2\text{CO}_3$  (5.2 g, 37.6 mmol), the ester **4** (5 g, 18.6 mmol), EtOH (15 ml), and  $(\text{H}_2\text{NC(SMe)NH})_2 \cdot \text{H}_2\text{SO}_4$  (5.2 g, 18.7 mmol) was stirred at room temperature for 1 week, neutralized with 1N HCl, the reaction product was filtered off, dried, and crystallized. Yield 4.0 g (70%); mp  $234-236^\circ\text{C}$  (DMF-EtOH) which agrees with literature data [9].

**2-Amino-6-diphenylmethyl-4(3H)-pyrimidinone Sesquihydrate (1a·1.5H<sub>2</sub>O).** A solution of ester **4** (5 g, 18.6 mmol),  $(\text{H}_2\text{N})_2\text{CNH}\cdot\text{AcOH}$  (4.5 g, 37.8 mmol), and NaOMe (3 g, 55.5 mmol) in abs. MeOH (100 ml) was boiled for 72 h with the exclusion of moisture and  $\text{CO}_2$ . The solvent was removed in vacuum, 1N AcOH (100 ml) was added to the residue, the desired product was filtered off, dried and crystallized. Yield 3.8 g (67%); mp  $167^\circ\text{C}$  (-  $\text{H}_2\text{O}$ ),  $237^\circ\text{C}$  anhydrous (EtOH).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm ( $J$ , Hz): 5.07 (1H, d,  $J = 6.11$ , 5-CH); 5.17 (1H, d,  $J = 4.89$ , CH); 6.51 (2H, s, NH<sub>2</sub>); 7.14-7.27 (10H, m,  $(\text{C}_6\text{H}_5)_2$ ); 10.70 (1H, s, NH). Found, %: C 66.50; H 6.01; N 13.73.  $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O} \cdot 1.5\text{H}_2\text{O}$ . Calculated, %: C 67.09; H 5.96; N 13.81.

**6-[Bromo(diphenyl)methyl]-2-(methylsulfanyl)-4(3H)-pyrimidinone (2b).** Bromine (0.35 ml, 1.09 g, 6.8 mmol) was added to a suspension of pyrimidinone **1b** (2 g, 6.8 mmol) in a mixture of anhydrous Py (6 ml, 5.87 g, 74.3 mmol) and anhydrous DMF (10 ml). The reaction mixture was stirred for 5 h at room temperature, diluted with water (150 ml) and extracted with  $\text{CHCl}_3$  ( $4 \times 50$  ml). The organic phase was consolidated, washed with water ( $2 \times 50$  ml), saturated  $\text{Na}_2\text{S}_2\text{O}_5$  (25 ml), the brine ( $2 \times 25$  ml), and dried over  $\text{Na}_2\text{SO}_4$ . It was filtered, the filtrate was concentrated in vacuum and the residue was concentrated in vacuum with toluene (25 ml) and crystallized. Yield 1.9 g (76%); mp 228–230°C (PhMe).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm ( $J$ , Hz): 2.23 (3H, s,  $\text{CH}_3$ ); 5.76 (1H, s, 5-CH); 7.18–7.26 (10H, s,  $(\text{C}_6\text{H}_5)_2$ ); 13.21 (1H, br. s, NH). Found, %: C 55.42; H 3.94; Br 20.60; N 7.03; S 8.07.  $\text{C}_{18}\text{H}_{15}\text{BrN}_2\text{OS}$ . Calculated, %: C 55.82; H 3.90; Br 20.63; N 7.23; S 8.28.

**2-Amino-6-[bromo(diphenyl)methyl]-4(3H)-pyrimidinone (2a)** was prepared analogously to compound **2b**. Yield 61%; mp 287–288°C (dec.) (EtOH).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 5.76 (1H, s, 5-CH); 6.65 (2H, s,  $\text{NH}_2$ ); 7.16–7.23 (10H, m,  $(\text{C}_6\text{H}_5)_2$ ); 11.31 (1H, s, NH). Found, %: C 56.99; H 3.90; Br 22.51; N 11.47.  $\text{C}_{17}\text{H}_{14}\text{BrN}_3\text{O}$ . Calculated, %: C 57.23; H 3.96; Br 22.43; N 11.80.

**2-Amino-6-[iodo(diphenyl)methyl]-4(3H)-pyrimidinone (4).** Pyrimidinone sesquihydrate **1a·1.5H<sub>2</sub>O** (1.5 g, 4.9 mmol) was added to solution of KOH (0.4 g, 6.0 mmol) in water (20 ml) and the mixture was heated to form a clear solution. The solution was cooled to room temperature,  $\text{CH}_2\text{Cl}_2$  (40 ml) and iodine (1.4 g, 5.5 mmol) were added and the reaction mixture was stirred vigorously at room temperature for 5 h, saturated aqueous solution of  $\text{Na}_2\text{S}_2\text{O}_5$  (10 ml) was added and the mixture was stirred for 5 min more. The precipitate was filtered off and crystallized. Yield 0.7 g (35%); mp 273–274°C (dec.) (EtOH–DMF).  $^1\text{H}$  NMR spectrum,  $\delta$ , ppm: 5.76 (1H, s, 5-CH); 6.60 (2H, s,  $\text{NH}_2$ ); 7.16–7.23 (10H, m,  $(\text{C}_6\text{H}_5)_2$ ); 11.14 (1H, s, NH). Found, %: C 50.50; H 3.50; I 30.99; N 10.33.  $\text{C}_{17}\text{H}_{14}\text{IN}_3\text{O}$ . Calculated, %: C 50.64; H 3.50; I 31.74; N 10.42.

## REFERENCES

1. M. Artico, S. Massa, A. Mai, M. E. Morongiu, G. Piras, E. Tramontano, and P. LaColla, *Antiviral. Chem. Chemother.*, **4**, 361 (1993).
2. R. Ragno, A. Mai, G. Sbardella, M. Artico, S. Massa, C. Musiu, M. Mura, F. Marturana, A. Cadeddu, and P. LaColla, *J. Med. Chem.*, **47**, 928 (2004).
3. A. Mai, M. Artico, G. Sbardella, S. Massa, A. G. Loi, E. Tramontano, P. Scano, and P. LaColla, *J. Med. Chem.*, **38**, 3258 (1995).
4. M. B. Nawrozkij, *Dis. Cand. Farm. Nauk. Pyatigorsk* (2002).
5. G. Sbardella, A. Mai, M. Artico, P. Chimenti, S. Massa, R. Loddo, M. E. Marongiu, and P. LaColla, *Antiviral. Chem. Chemother.*, **12**, 37 (2001).
6. A. V. Dombrovskii, *Zh. Obshch. Khim.*, **24**, 610 (1954).
7. I. A. Novakov, B. S. Orlinson, and M. B. Nawrozkij, Russ. Pat. 2238269; <http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=RU2238269&F=0>
8. I. A. Novakov, B. S. Orlinson, and M. B. Navrotskii, positive solution on the conveyance of Russian Pat. from 20.01.2005 to declaration No. 2003138160.
9. M. B. Nawrozkij, *Khim.-Farm. Zh.*, **37**, 22 (2003).